Claims
- 1.) An isolated nucleic acid derived from a human gene encoding a protein selected from a member of the group consisting of the human OATP2 protein, and human cMOAT protein, wherein said nucleic acid comprises at least one polymorphic position.
- 2.) The isolated nucleic acid of claim 1 wherein said at least one polymorphic position for each said gene is a polymorphic position specified in Table IV, V, or complement thereof.
- 3.) The isolated nucleic acid of claim 2 wherein the sequence at said at least one polymorphic position is depicted in a nucleic acid sequence selected from the group consisting of SEQ ID NO: 5, 7, 9, 11, 13, 15, 17, 19, 21,23, 25, 27, 29, 31,33, 35,37, 39,41,43,45,47,49, 603, 51 to 326, or complement thereof.
- 4.) The isolated nucleic acid of claim 3 wherein said at least one polymorphic position resides in a member of the group consisting of: a non-coding position within the genomic sequence of said gene; a coding position within the genomic sequence of said gene; a coding position which results in a missense mutation of the translated product of said gene; a coding position that results in a silent mutation of the translated product of said gene; a non-coding position that resides within the untranslated region of said gene; and a non-coding position that resides within an intronic region of said gene.
- 5.) The isolated nucleic acid molecule according to claim 4, wherein said nucleic acid sequence is at least 15 nucleotides in length.
- 6.) The isolated nucleic acid molecule according to claim 4, wherein said nucleic acid sequence is at least 30 nucleotides in length.
- 7.) The isolated nucleic acid molecule according to claim 4, wherein said nucleic acid sequence is at least 40 nucleotides in length.
- 8.) A probe that hybridizes to a polymorphic position defined in claim 2.
- 9.) The probe of claim 8 wherein said probe is at least 15 nucleotides in length.
- 10.) The probe of claim 9 wherein a central position of the probe aligns with said polymorphic position.
- 11.) The probe of claim 9 wherein the 3′ end of the primer aligns with said polymorphic position.
- 12.) A method of analyzing at least one nucleic acid sample, comprising the steps of (1) obtaining a nucleic acid sample from one or more individuals; and (2) determining the nucleic acid sequence at one or more polymorphic positions in a gene encoding a protein selected from the group consisting of the human OATP2 protein, and human cMOAT protein, wherein the presence of a reference allele at said position(s) correlates to a phenotype.
- 13.) A method of identifying at least one nucleic acid sample that correlates to a phenotype, comprising the steps of (1) obtaining said nucleic acid sample from one or more individuals; and (2) determining the nucleic acid sequence at one or more polymorphic positions in a gene encoding a protein selected from the group consisting of the human OATP2 protein, and human cMOAT protein, wherein the presence of a alternate allele at said position(s) correlates to said phenotype.
- 14.) The method according to claim 12, wherein the phenotype is selected from the group consisting of: low hepatic statin uptake, decreased statin response; increased risk of developing drug interactions upon administration of at least one statin; increased susceptibility for developing a cardiovascular disorder; increased susceptibility for developing high cholesterol levels, metabolic dieases, inflammatory diseases, hypertension, and congestive heart failure; increased susceptibility for having low efficious response to pravastatin therapy; increased susceptibility for having decreased ability to transport compounds by organic anion transporters; increased susceptibility for having decreased ability to transport compounds by organic anion transporters in the liver; increased susceptibility for developing liver disease; increased susceptibility for developing a disease associated with low levels of low-density lipoprotein cholesterol; increased susceptibility to develop multidrug resistance; increased susceptibility to to have decreased response to HMG-CoA reductase inhibitor therapy; increased susceptibility for developing a disorder due to decreased hepatic or cellular uptake of taurocholate, estrone sulfate, estradiol 17-D-glucuronide, leukotriene C4, prostaglandin E2, or thyroid hormone.
- 15.) The method according to claim 13, wherein the phenotype is selected from the group consisting of: low hepatic statin uptake, decreased statin response; increased risk of developing drug interactions upon administration of at least one statin; increased susceptibility for developing a cardiovascular disorder; increased susceptibility for developing high cholesterol levels, metabolic dieases, inflammatory diseases, hypertension, and congestive heart failure; increased susceptibility for having low efficious response to pravastatin therapy; increased susceptibility for having decreased ability to transport compounds by organic anion transporters; increased susceptibility for having decreased ability to transport compounds by organic anion transporters in the liver; increased susceptibility for developing liver disease; increased susceptibility for developing a disease associated with low levels of low-density lipoprotein cholesterol; increased susceptibility to develop multidrug resistance; increased susceptibility to to have decreased response to HMG-CoA reductase inhibitor therapy; increased susceptibility for developing a disorder due to decreased hepatic or cellular uptake of taurocholate, estrone sulfate, estradiol 1 7-D-glucuronide, leukotriene C4, prostaglandin E2, or thyroid hormone.
- 16.) A kit for identifying an individual at risk of developing a phenotype, said kit comprising
i.) sequencing primers, and ii.) sequencing reagents,
wherein said primers are primers that hybridize to at least one polymorphic position in a human gene selected from the group consisting of human OATP2 protein, and human cMOAT protein.
- 17.) The kit according to claim 16 wherein said polymorphic positions are selected from a group consisting of the polymorphic positions provided in Table IV, or V.
- 18.) The kit according to claim 17 wherein the sequence at said at least one polymorphic position is depicted in a nucleic acid sequence selected from the group consisting of SEQ ID NO: 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 603, 51 to 326, or complement thereof.
- 19.) The kit according to claim 17 wherein the wherein the phenotype is selected from the group consisting of: low hepatic statin uptake, decreased statin response; increased risk of developing drug interactions upon administration of at least one statin; increased susceptibility for developing a cardiovascular disorder; increased susceptibility for developing high cholesterol levels, metabolic dieases, inflammatory diseases, hypertension, and congestive heart failure; increased susceptibility for having low efficious response to pravastatin therapy; increased susceptibility for having decreased ability to transport compounds by organic anion transporters; increased susceptibility for having decreased ability to transport compounds by organic anion transporters in the liver; increased susceptibility for developing liver disease; increased susceptibility for developing a disease associated with low levels of low-density lipoprotein cholesterol; increased susceptibility to develop multidrug resistance; increased susceptibility to to have decreased response to HMG-CoA reductase inhibitor therapy; increased susceptibility for developing a disorder due to decreased hepatic or cellular uptake of taurocholate, estrone sulfate, estradiol 17-D-glucuronide, leukotriene C4, prostaglandin E2, or thyroid hormone.
Parent Case Info
[0001] This application claims benefit to provisional application U.S. Serial No. 60/324,172 filed Sep. 21, 2001; and to provisional application U.S. Serial No. 60/333,700 filed Nov. 27, 2001. The entire teachings of the referenced applications are incorporated herein by reference.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60324172 |
Sep 2001 |
US |
|
60333700 |
Nov 2001 |
US |